Valuation : Theracryf Plc

Market Cap 5.38M 4.63M 4.35M 3.98M 7.42M 509M 7.48M 51.4M 20.02M 260M 20.21M 19.77M 837M P/E 2026 *
-1.25x
P/E 2027 * -1.67x
Enterprise Value 3.23M 2.77M 2.6M 2.38M 4.45M 305M 4.48M 30.8M 12M 156M 12.11M 11.85M 502M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
1 day-2.63%
1 week-2.63%
Current month-2.63%
1 month-7.50%
3 months-22.92%
6 months-9.76%
Current year-7.50%
1 week 0.18
Extreme 0.18
0.2
1 month 0.16
Extreme 0.16
0.21
Current year 0.16
Extreme 0.16
0.27
1 year 0.16
Extreme 0.16
0.27
3 years 0.16
Extreme 0.16
2.52
5 years 0.16
Extreme 0.16
7.8
10 years 0.16
Extreme 0.16
33.1
Manager TitleAgeSince
Chief Executive Officer 64 01/10/2020
Director of Finance/CFO - 05/09/2023
Chief Tech/Sci/R&D Officer - 01/05/2021
Director TitleAgeSince
Director/Board Member - 14/10/2015
Director/Board Member 64 01/10/2020
Director/Board Member - 01/01/2024
Date Insider Type Main position Quantity % Market Cap. Importance
16/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
22/5/25 Others

Director

422,727,272 19.8499%
4/3/25 Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
-2.63%-2.63%-26.00%-91.96% 5.38M
+0.41%-2.07%+41.26%+95.40% 69.02B
+1.31%+0.55%+49.48%+90.80% 66.32B
+0.04%+4.36%-11.72%+459.54% 27.66B
-0.90%-7.65%+2.45%-15.50% 25.84B
-2.45%-2.11%+40.53%+10.30% 26.54B
+1.01%+1.38%+26.48%-17.16% 20.4B
+3.45%-13.46%+222.69%+389.50% 17.63B
-0.81%-4.22%+0.28%+534.64% 15.15B
+1.03%+7.00%+59.98%+160.03% 14.65B
Average +0.07%-1.50%+40.54%+161.56% 28.32B
Weighted average by Cap. +0.42%-0.83%+43.41%+148.83%

Financials

2026 *2027 *
Net sales - -
Net income -3.38M -2.91M -2.73M -2.5M -4.66M -319M -4.7M -32.28M -12.57M -163M -12.69M -12.41M -526M -3.46M -2.98M -2.79M -2.55M -4.77M -327M -4.81M -33.03M -12.86M -167M -12.99M -12.7M -538M
Net Debt -2.16M -1.86M -1.74M -1.59M -2.97M -204M -3M -20.6M -8.02M -104M -8.1M -7.92M -336M -704K -606K -568K -520K -971K -66.54M -978K -6.72M -2.62M -34.01M -2.64M -2.59M -110M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
03/09/26 GBX 0.1850 -2.63% 4,374,025
02/09/26 GBX 0.1900 0.00% 593,023
01/09/26 GBX 0.1900 0.00% 405,000
28/08/26 GBX 0.1900 0.00% 1,799,771
27/08/26 GBX 0.1900 0.00% 668,009
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002504USD
Average target price
0.0431USD
Spread / Average Target
+1,622.62%

Annual profits - Rate of surprise